KRAS and familial pancreatic carcinoma: In SCCHN, miR-193b acts as an oncogene through its action on NF1, and in pancreatic cancer, it acts as a tumor suppressor by directly targeting KRAS through AKT, ERK, and MAPK pathways [207].